Literature DB >> 1854557

The effect of heparin on three whole blood activated clotting tests and thrombin time.

D L Uden1, R E Seay, P J Kriesmer, R J Cipolle, N R Payne.   

Abstract

Whole blood activated clotting time (ACT) can be determined by many different methods that use a variety of clotting cascade activators and end-points. This study compared the results of three whole blood ACT instruments at equivalent concentrations of heparin. Whole blood (9.8 ml) from 10 healthy adult volunteers without coagulation abnormalities was added to 0.2 ml of heparin solution producing heparin concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, and 1.0 U/ml. Coagulation status was determined in duplicate with the Hemochron 400 System (HC), the HemoTec Automated Coagulation Timer (HT), and the TriMed ACTivator (TM). Thrombin times or dilutions (TT) were also determined for each sample. Baseline values did not differ (p greater than 0.05); however, the HT and TM ACT values were significantly longer (p less than 0.05) than the HC ACT values at predicted heparin concentrations greater than 0.2 U/ml. Results from the HT and TM instruments were not significantly different. The HT and TM instruments both provided a greater ACT range over the heparin concentrations tested. Of the tests studied to monitor heparin therapy, mean scaled TTs showed the best correlation with predicted heparin concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854557

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN: 0889-7190


  2 in total

Review 1.  Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1993

2.  Antiphospholipid Syndrome and Cardiac Bypass: The Careful Balance between Clotting and Bleeding.

Authors:  Kelly Ural; Jaclyn Edelson
Journal:  J Extra Corpor Technol       Date:  2021-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.